Re-immunisation schedule in leukaemic children after intensive chemotherapy: A possible strategy

Francesca Fioredda, Alessandro Plebani, Guia Hanau, Riccardo Haupt, Mareva Giacchino, Elena Barisone, Luciano Balbo, Elio Castagnola

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The aim of this retrospective study was to test the residual humoral immunity to compulsory vaccines after the end of chemotherapy for acute lymphoblastic leukaemia in a cohort of 70 Italian children. All the patients, who had been immunised according to the Italian schedule prior to the disease, were tested for antibody levels against tetanus and hepatitis B at a median of 10 months after the end of therapy. Median age at diagnosis of leukaemia was 48 months, and median age at vaccine titration was 84 months. The protective level of antibodies for tetanus and hepatitis B was shown in 83% and 81% of patients, respectively; the remaining 17% and 19% were not protected against the two pathogens. Double negativity was observed in only four of 62 (6%) patients in the cohort. These data were comparable with published data regarding healthy children of the same age and from the same geographical areas. Therefore, given the direct and indirect costs of performing laboratory tests, as well as the cost of revaccination, our proposal is to continue the vaccination schedule according to the child's age without any titration screening 6 months after the end of therapy. Larger studies are needed to confirm these observations.

Original languageEnglish
Pages (from-to)20-23
Number of pages4
JournalEuropean Journal of Haematology
Volume74
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Immunization Schedule
Tetanus
Drug Therapy
Appointments and Schedules
Vaccines
Hepatitis B Antibodies
Secondary Immunization
Costs and Cost Analysis
Humoral Immunity
Hepatitis B
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Vaccination
Retrospective Studies
Antibodies
Therapeutics

Keywords

  • Acute lymphoblastic leukaemia
  • Immunocompromised children
  • Re-immunisation schedule
  • Residual immunity

ASJC Scopus subject areas

  • Hematology

Cite this

Re-immunisation schedule in leukaemic children after intensive chemotherapy : A possible strategy. / Fioredda, Francesca; Plebani, Alessandro; Hanau, Guia; Haupt, Riccardo; Giacchino, Mareva; Barisone, Elena; Balbo, Luciano; Castagnola, Elio.

In: European Journal of Haematology, Vol. 74, No. 1, 01.2005, p. 20-23.

Research output: Contribution to journalArticle

Fioredda, Francesca ; Plebani, Alessandro ; Hanau, Guia ; Haupt, Riccardo ; Giacchino, Mareva ; Barisone, Elena ; Balbo, Luciano ; Castagnola, Elio. / Re-immunisation schedule in leukaemic children after intensive chemotherapy : A possible strategy. In: European Journal of Haematology. 2005 ; Vol. 74, No. 1. pp. 20-23.
@article{91a21d2c061647c39441292a4400ac5d,
title = "Re-immunisation schedule in leukaemic children after intensive chemotherapy: A possible strategy",
abstract = "The aim of this retrospective study was to test the residual humoral immunity to compulsory vaccines after the end of chemotherapy for acute lymphoblastic leukaemia in a cohort of 70 Italian children. All the patients, who had been immunised according to the Italian schedule prior to the disease, were tested for antibody levels against tetanus and hepatitis B at a median of 10 months after the end of therapy. Median age at diagnosis of leukaemia was 48 months, and median age at vaccine titration was 84 months. The protective level of antibodies for tetanus and hepatitis B was shown in 83{\%} and 81{\%} of patients, respectively; the remaining 17{\%} and 19{\%} were not protected against the two pathogens. Double negativity was observed in only four of 62 (6{\%}) patients in the cohort. These data were comparable with published data regarding healthy children of the same age and from the same geographical areas. Therefore, given the direct and indirect costs of performing laboratory tests, as well as the cost of revaccination, our proposal is to continue the vaccination schedule according to the child's age without any titration screening 6 months after the end of therapy. Larger studies are needed to confirm these observations.",
keywords = "Acute lymphoblastic leukaemia, Immunocompromised children, Re-immunisation schedule, Residual immunity",
author = "Francesca Fioredda and Alessandro Plebani and Guia Hanau and Riccardo Haupt and Mareva Giacchino and Elena Barisone and Luciano Balbo and Elio Castagnola",
year = "2005",
month = "1",
doi = "10.1111/j.1600-0609.2004.00340.x",
language = "English",
volume = "74",
pages = "20--23",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Re-immunisation schedule in leukaemic children after intensive chemotherapy

T2 - A possible strategy

AU - Fioredda, Francesca

AU - Plebani, Alessandro

AU - Hanau, Guia

AU - Haupt, Riccardo

AU - Giacchino, Mareva

AU - Barisone, Elena

AU - Balbo, Luciano

AU - Castagnola, Elio

PY - 2005/1

Y1 - 2005/1

N2 - The aim of this retrospective study was to test the residual humoral immunity to compulsory vaccines after the end of chemotherapy for acute lymphoblastic leukaemia in a cohort of 70 Italian children. All the patients, who had been immunised according to the Italian schedule prior to the disease, were tested for antibody levels against tetanus and hepatitis B at a median of 10 months after the end of therapy. Median age at diagnosis of leukaemia was 48 months, and median age at vaccine titration was 84 months. The protective level of antibodies for tetanus and hepatitis B was shown in 83% and 81% of patients, respectively; the remaining 17% and 19% were not protected against the two pathogens. Double negativity was observed in only four of 62 (6%) patients in the cohort. These data were comparable with published data regarding healthy children of the same age and from the same geographical areas. Therefore, given the direct and indirect costs of performing laboratory tests, as well as the cost of revaccination, our proposal is to continue the vaccination schedule according to the child's age without any titration screening 6 months after the end of therapy. Larger studies are needed to confirm these observations.

AB - The aim of this retrospective study was to test the residual humoral immunity to compulsory vaccines after the end of chemotherapy for acute lymphoblastic leukaemia in a cohort of 70 Italian children. All the patients, who had been immunised according to the Italian schedule prior to the disease, were tested for antibody levels against tetanus and hepatitis B at a median of 10 months after the end of therapy. Median age at diagnosis of leukaemia was 48 months, and median age at vaccine titration was 84 months. The protective level of antibodies for tetanus and hepatitis B was shown in 83% and 81% of patients, respectively; the remaining 17% and 19% were not protected against the two pathogens. Double negativity was observed in only four of 62 (6%) patients in the cohort. These data were comparable with published data regarding healthy children of the same age and from the same geographical areas. Therefore, given the direct and indirect costs of performing laboratory tests, as well as the cost of revaccination, our proposal is to continue the vaccination schedule according to the child's age without any titration screening 6 months after the end of therapy. Larger studies are needed to confirm these observations.

KW - Acute lymphoblastic leukaemia

KW - Immunocompromised children

KW - Re-immunisation schedule

KW - Residual immunity

UR - http://www.scopus.com/inward/record.url?scp=12444292837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444292837&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2004.00340.x

DO - 10.1111/j.1600-0609.2004.00340.x

M3 - Article

C2 - 15613102

AN - SCOPUS:12444292837

VL - 74

SP - 20

EP - 23

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -